间皮素
嵌合抗原受体
医学
细胞因子释放综合征
卵巢癌
癌症研究
过继性细胞移植
T细胞
免疫疗法
免疫学
细胞因子
抗原
癌症
内科学
免疫系统
作者
Janos Laszlo Tanyi,Caitlin Stashwick,Gabriela Plesa,Mark Aloysuis Morgan,David L. Porter,Marcela Valderrama Maus,Carl H. June
标识
DOI:10.1097/cji.0000000000000160
摘要
Cytokine release syndrome (CRS) is a potentially severe systemic toxicity seen after adoptive T-cell therapy and caused by T-cell activation and proliferation and is associated with elevated circulating levels of cytokines such as C-reactive protein, interleukin-6 (IL-6), and interferon-γ and has previously been described as a systemic response in hematologic malignancies. A 52-year-old woman with BRCA 1 mutation positive heavily pretreated advanced recurrent serous ovarian cancer was treated under a compassionate use protocol with autologous mesothelin-redirected chimeric antigen receptor T cells (CART-meso). Autologous T cells were transduced to express a receptor composed of an extracellular antimesothelin single-chain variable fragment fused to 4-1BB and TCR-zeta signaling domain. This patient was infused with 3×10 CART-meso T cells/m without lymphodepletion and developed compartmental CRS confined to the pleural cavities. The compartmental CRS was evidenced by an increase in IL-6 and accumulation of CART-meso T cells in pleural fluid compared with peripheral blood and was successfully treated the anti-IL6 receptor antagonist tocilizumab on D21 after the T-cell infusion. This is the first description of a compartmental CRS in a patient with solid malignancy. This response could be due to malignant pleural fluid creating an environment where T cells could interact with tumor cells and suggests localized on-target CAR-T-cell activation.
科研通智能强力驱动
Strongly Powered by AbleSci AI